Q3 2020 Sales Performance

Deep dive: Using our science and technology for global health gsk We aim to improve global health impact through R&D for infectious diseases that affect children and young people in developing countries focusing on HIV, malaria and TB HIV FDA has approved paediatric dolutegravir, and we have filed an EU regulatory submission in partnership with the International Maternal Paediatric Adolescent AIDS Clinical Trials Network and the Paediatric European Network for Treatment of AIDS. Malaria Krintafel/Kozenis (tafenoquine), our single dose radical cure treatment for P. vivax malaria, developed in partnership with the Medicines for Malaria Venture, has been approved by the US FDA, the Australian TGA and in malaria endemic countries Brazil and Thailand. Our RTS,S vaccine aims to protect children from P. falciparum malaria. A pilot vaccine implementation programme coordinated by the WHO has launched in selected areas of Malawi, Ghana and Kenya. At least 360,000 children per year for five years will receive the vaccine. TB Released positive final phase II results for our candidate TB vaccine and built a collaboration with the Bill & Melinda Gates Medical Research Institute for the continued development of the asset for developing countries 15

View entire presentation